Figure 1. In vitro effects of CB-839 on patient-derived melanoma cell lines and autologous TILs.
(A) Glutamine (Gln) consumption by the indicated melanoma cell lines treated with vehicle or 1µmol/L CB-839 for 12h. (B) Basal oxygen consumption rate (OCR) by the cell lines treated with vehicle or 1µmol/L CB-839 for 24h. (C) Glutamine (Gln) consumption by the indicated TILs treated with vehicle or 1µmol/L CB-839 for 12h. (D) Growth of four melanoma cell lines measured after 72 h treatment of the cells with increasing doses of CB-839. (E–H) Apoptosis assay in an in vitro adoptive T-cell therapy experiment, showing percent activation of caspase 3 in melanoma cells by treatments with single agent CB-839, patient-specific adoptive TILs, or their combinations. Data is average of quadruplicate samples for the seahorse experiment in B, and average of triplicate samples for the others. Error bars represent standard deviation (SD). Significant treatment-induced differences (p<0.05) in results are indicated by ‘*’.